Arch Biopartners Inc.

Published purpose

The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs. This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.